Portfolio company HI-Bio (Human Immunology Biosciences) acquired by Biogen (~$1.15B upfront, up to $650M in milestones).
HI-Bio is a clinical-stage biotechnology company focused on discovering and developing precision medicines for patients suffering from immune-mediated diseases (IMDs)
HI-Bio is a clinical-stage biotechnology company focused on discovering and developing precision medicines for patients suffering from immune-mediated diseases (IMDs). The company specializes in targeted therapies, particularly its lead asset, felzartamab, which is an antibody aimed at treating severe kidney diseases.